Skip to main content

Drug Pricing Reforms Keep Pressure on Biotech, Healthcare ETFs

Healthcare and biotechnology-related ETFs are taking a blow as drug-pricing reforms weigh on the sector outlook. The Health Care Select Sector SPDR ETF (NYSEArca: XLV) fell another 0.6% and the iShares Nasdaq Biotechnology ETF (IBB) declined 2.0% in back-to-back selling on Thursday. The biotech...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.